Ian Flinn, MD, PhD

Articles by Ian Flinn, MD, PhD

Dr. Flinn on the FDA Approval of Zanubrutinib in CLL/SLL

January 24th 2023

Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

ByBijal D. Shah, MD,Caron Jacobson, MD,Luhua (Michael) Wang, MD,Ian Flinn, MD, PhD,Brian T. Hill, MD, PhD

January 21st 2022

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Second-Line Therapy for MCL: Differentiating Available BTK Inhibitors

ByBijal D. Shah, MD,Caron Jacobson, MD,Luhua (Michael) Wang, MD,Ian Flinn, MD, PhD,Brian T. Hill, MD, PhD

January 21st 2022

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Dr. Flinn on the Utility of Tafasitamab in Relapsed/Refractory DLBCL

ByIan Flinn, MD, PhD

June 12th 2020

Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).

Dr. Flinn on the iNNOVATE Trial in Waldenstrom Macroglobulinemia

ByIan Flinn, MD, PhD

August 7th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.

Dr. Flinn on the RELEVANCE Trial in Follicular Lymphoma

ByIan Flinn, MD, PhD

July 16th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.